Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$1485.00
-119.00 (-7.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-54.0B · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$82.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.7%
↓Gross Margin
13.1%
↓Debt/Equity
1.00
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-33.7%
FCF CAGR
—
FCF margin
-67.2%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $41.98B · net income $-29.96B · FCF $-28.20B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $41.98B | $41.98B | $173.60B | $159.90B | $144.30B |
| Net Income | $-29.96B | $-29.96B | $-52.79B | $-23.29B | $-47.22B |
| EBITDA | $-12.49B | $-12.49B | $-26.34B | $1.37B | $-30.45B |
| EPS | -543.00 | -543.00 | -961.00 | -584.00 | -557.20 |
| Gross Margin | 13.1% | 13.1% | 29.1% | 34.5% | 31.9% |
| Operating Margin | -36.0% | -36.0% | -4.0% | 0.0% | -3.4% |
| Net Margin | -71.4% | -71.4% | -30.4% | -14.6% | -32.7% |
| Balance Sheet | |||||
| Debt/Equity | 1.00 | 1.00 | 0.98 | 0.85 | 1.09 |
| Current Ratio | 1.07 | 1.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-28.20B | $-28.20B | $-63.15B | $-53.96B | $-69.75B |
| Returns | |||||
| ROE | -31.7% | -31.7% | -43.1% | -13.2% | -35.8% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 300.83 | — |
| P/B | 0.87 | 0.87 | 1.75 | 1.63 | 2.95 |
| Growth & Yield | |||||
| Revenue Growth | -75.8% | -75.8% | 8.6% | 10.8% | — |
| EPS Growth | 43.5% | 43.5% | -64.6% | -4.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-961.00 → -543.00
Residual
-53.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.